Premium
A low percentage of HER ‐2 amplification whereas indicates poor prognosis in salivary carcinoma ex pleomorphic adenoma: a study of 140 cases
Author(s) -
Xia Liang,
Hu Yuhua,
Li Jiang,
Gu Ting,
Zhang Chunye,
Wang Lizhen,
Tian Zhen
Publication year - 2017
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/jop.12477
Subject(s) - carcinoma ex pleomorphic adenoma , malignancy , pleomorphic adenoma , carcinoma , medicine , pathology , immunohistochemistry , epidermal growth factor receptor , adenoma , fluorescence in situ hybridization , oncology , salivary gland , cancer , biology , gene , biochemistry , chromosome
Background Human epidermal growth factor receptor 2 ( HER ‐2 ) has been found in many malignant tumours including salivary malignancy. HER ‐2 ‐targeted therapy has been applied in the treatment of HER ‐2 ‐overexpressing carcinoma. The aim of this study was to determine the status of HER ‐2 in salivary invasive carcinoma ex pleomorphic adenoma ( ICXPA ) in a relatively large Chinese sample, which may provide HER ‐2 ‐targeted therapy with profound support in the future. Methods and results We collected 140 ICXPA s and their related clinicopathological and follow‐up data. All cases were examined for HER ‐2 expression by immunohistochemistry and gene amplification by fluorescence in situ hybridization, if necessary. The study showed that the ratio of HER ‐2 positivity was only 25% (35/140) in all cases, but the positive ratio in ICXPA s with luminal differentiation for malignant component (32/79, 40.5%) was much higher than that in cases with non‐luminal differentiation (3/61, 4.9%). The overexpression of HER ‐2 was closely associated with gender, histological grade and N stage. HER ‐2 ‐positive tumours conferred short overall survival time ( P = 0.036) and short disease‐specific survival time ( P = 0.042) in patients, but HER ‐2 status was not an independent predictor of prognosis. Conclusions Human epidermal growth factor receptor 2 amplification is significantly associated with cell differentiation of the malignant component in ICXPA and it implies an unfavourable prognosis. Although HER ‐2 positivity is not common in the tumour, HER ‐2‐ targeted therapy for those HER ‐2 ‐positive patients is still worth expecting.